AU2017230792B2 - Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses - Google Patents

Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses Download PDF

Info

Publication number
AU2017230792B2
AU2017230792B2 AU2017230792A AU2017230792A AU2017230792B2 AU 2017230792 B2 AU2017230792 B2 AU 2017230792B2 AU 2017230792 A AU2017230792 A AU 2017230792A AU 2017230792 A AU2017230792 A AU 2017230792A AU 2017230792 B2 AU2017230792 B2 AU 2017230792B2
Authority
AU
Australia
Prior art keywords
leu
ser
ala
glu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017230792A
Other languages
English (en)
Other versions
AU2017230792A1 (en
AU2017230792A8 (en
Inventor
William R. Bishai
Cynthia K. BULLEN
Laurene CHEUNG
Shashank Gupta
John R. Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Johns Hopkins University
Original Assignee
Boston University
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, Johns Hopkins University filed Critical Boston University
Publication of AU2017230792A1 publication Critical patent/AU2017230792A1/en
Publication of AU2017230792A8 publication Critical patent/AU2017230792A8/en
Application granted granted Critical
Publication of AU2017230792B2 publication Critical patent/AU2017230792B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017230792A 2016-03-10 2017-03-10 Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses Active AU2017230792B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306281P 2016-03-10 2016-03-10
US62/306,281 2016-03-10
PCT/US2017/021715 WO2017156356A1 (en) 2016-03-10 2017-03-10 Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses

Publications (3)

Publication Number Publication Date
AU2017230792A1 AU2017230792A1 (en) 2018-10-18
AU2017230792A8 AU2017230792A8 (en) 2018-11-29
AU2017230792B2 true AU2017230792B2 (en) 2023-08-10

Family

ID=59789900

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017230792A Active AU2017230792B2 (en) 2016-03-10 2017-03-10 Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses

Country Status (12)

Country Link
US (1) US10988512B2 (https=)
EP (1) EP3426785A4 (https=)
JP (2) JP2019512233A (https=)
KR (1) KR102430891B1 (https=)
CN (2) CN118599011A (https=)
AU (1) AU2017230792B2 (https=)
BR (1) BR112018068055A2 (https=)
CA (1) CA3017143A1 (https=)
IL (2) IL261660A (https=)
MX (1) MX2018010850A (https=)
WO (2) WO2017156356A1 (https=)
ZA (1) ZA201806450B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3762401A4 (en) * 2018-03-06 2021-12-08 The Johns Hopkins University CANCER TREATMENT OR PREVENTION METHODS USING TREG DEPLETING AGENT AND CHECKPOINT INHIBITOR
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
MX2022000052A (es) * 2019-07-01 2022-04-06 Eisai R&D Man Co Ltd Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766.
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
KR20230102682A (ko) * 2021-12-30 2023-07-07 (주)셀트리온 목적 단백질의 발현 방법
CN114903896B (zh) * 2022-05-30 2023-07-25 广西大学 贝达喹啉在制备治疗弓形虫病药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012039954A2 (en) * 2010-09-08 2012-03-29 The Scripps Research Institute Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns
US20120149650A1 (en) * 2003-11-25 2012-06-14 Anjin Group, Inc. Diphtheria Toxin Variant

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549855B1 (fr) * 1983-07-29 1987-03-27 Grp Genie Genetique Sequence nucleotidique codant pour le peptide signal de la toxine diphterique, vecteur contenant cette sequence nucleotidique, leur application a la transformation de micro-organismes et compositions peptidiques obtenues
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
CA1340494C (en) * 1988-05-19 1999-04-13 The Beth Israel Hospital Association And Brigham And Women's Hospital Induction of tolerance to a foreign antigen
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
WO1991013090A1 (en) 1990-03-02 1991-09-05 Diane Williams Improved chimeric toxins
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
NO175188C (no) * 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DK0590060T3 (da) 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5654273A (en) 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2004007663A2 (en) 2002-05-22 2004-01-22 Advanced Microbial Solutions Corporation Gene expression using metal ion dependent repressor/operator tandems
AU2006260240B2 (en) * 2005-06-21 2012-03-15 The Research Foundation For Microbial Diseases Of Osaka University Therapeutic agent for cancer
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
EP2600843B9 (en) * 2010-07-19 2020-03-11 Pressure BioSciences, Inc. Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
WO2012110596A1 (en) * 2011-02-16 2012-08-23 Friedrich-Alexander-Universität Erlangen-Nürnberg Fusion protein for the treatment of immunologic or allergic reactions
KR101895768B1 (ko) * 2011-06-01 2018-09-07 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
US8906681B2 (en) * 2011-08-02 2014-12-09 The Scripps Research Institute Reliable stabilization of N-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120149650A1 (en) * 2003-11-25 2012-06-14 Anjin Group, Inc. Diphtheria Toxin Variant
US8865866B2 (en) * 2003-11-25 2014-10-21 Anjin Group, Inc. Diphtheria toxin variant
WO2012039954A2 (en) * 2010-09-08 2012-03-29 The Scripps Research Institute Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GenBank [O] 23 July 1993 (1993-07-23), XP055425412, Database accession no. AAA72359.1 *

Also Published As

Publication number Publication date
CN109790545A (zh) 2019-05-21
WO2017156356A1 (en) 2017-09-14
CA3017143A1 (en) 2017-09-14
US20190071472A1 (en) 2019-03-07
CN118599011A (zh) 2024-09-06
KR102430891B1 (ko) 2022-08-09
ZA201806450B (en) 2020-12-23
IL291586A (en) 2022-05-01
EP3426785A1 (en) 2019-01-16
MX2018010850A (es) 2019-05-15
AU2017230792A1 (en) 2018-10-18
JP2019512233A (ja) 2019-05-16
WO2018164712A1 (en) 2018-09-13
EP3426785A4 (en) 2019-12-25
AU2017230792A8 (en) 2018-11-29
IL261660A (en) 2018-10-31
JP2023011857A (ja) 2023-01-24
BR112018068055A2 (pt) 2019-01-08
KR20190016934A (ko) 2019-02-19
US10988512B2 (en) 2021-04-27
JP7532475B2 (ja) 2024-08-13

Similar Documents

Publication Publication Date Title
AU2017230792B2 (en) Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
KR101078919B1 (ko) 신규한 스트렙토코커스 항원
EP1054971B1 (en) Group b streptococcus antigens
US20100247560A1 (en) Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
EA021168B1 (ru) Пегилированная l-аспарагиназа
EP1741718A2 (en) Expression of lipoproteins
WO1994024155A1 (en) The therapeutic use of clostridium difficile toxin a
JP5097544B2 (ja) 炭疽菌からの防御抗原の調製
US12186376B2 (en) Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
JP2002505083A (ja) 組換え脂質化ＰｓａＡタンパク質、調製法および使用
JP2012510289A (ja) グルタミルｔＲＮＡ合成酵素（ＧｔＳ）フラグメント
US11965009B2 (en) Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
JP4749641B2 (ja) ワクチン用の肺炎球菌タンパク質の相同体および断片
US11203626B2 (en) Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
EP1108038A1 (en) Superoxide dismutase as a vaccine antigen
CN104321078A (zh) 抗原和抗原组合
US20050238657A1 (en) Defective entities and uses therefor
AU2007202175B2 (en) Group B Streptococcus Antigens
CN100469871C (zh) 一种低热原葡激酶及其制备方法
HK1100752A (en) Group b streptococcus antigens

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 40 , PAGE(S) 5619 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME THE JOHNS HOPKINS UNIVERSITY, THE TRUSTEES OF BOSTON UNIVERSITY, APPLICATION NO. 2017230792, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO TRUSTEES OF BOSTON UNIVERSITY

FGA Letters patent sealed or granted (standard patent)